Collaboration to Accelerate Translation of Multiplexed Methods to Quantify Type 2 Diabetes Markers Announced  

Scientists at Nuclea Biotechnologies, Inc and Thermo Fisher Scientific are pooling their expertise to develop novel multiplexed research methods for high-throughput quantification of native insulin and its therapeutic analogues. Monitoring the levels of these markers may be useful in predicting the response to therapy for Type 2 diabetes.
 
Nuclea has extensive experience in developing and commercialising biomarkers and clinical tests. The Thermo Fisher Scientific Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center has successfully collaborated with numerous leading clinical researchers to apply mass spectrometry (MS) to biomarker discovery and its translation to high-throughput, quantitative methods.
 
“We’ve already worked with the BRIMS Center to develop two other very important assays,” said Nuclea CEO, Patrick Muraca. “These assays have demonstrated the sensitivity, precision and robustness needed for high-throughput detection of clinically relevant isoforms of target proteins.”

“The real-world application of multiplexed MS-based methods to Type 2 diabetes presents an opportunity to advance research in this crucial area.” said Mary Lopez, Director of the BRIMS Center, Thermo Fisher Scientific. “Nuclea’s proven ability to validate and develop routine assays means our collaboration can support research efforts.”
 
Scientists from Nuclea and the BRIMS Center will develop multiplexed MS-based research methods that Nuclea will use to analyse donor plasma samples from Boston-based diabetes research collaborations. A proprietary platform that combines Thermo Scientific MSIA immuno-enrichment technology, TSQ Vantage or Quantiva triple quadrupole mass spectrometers and Pinpoint Software will be used for the collaborative work.